<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804648</url>
  </required_header>
  <id_info>
    <org_study_id>VPH0111</org_study_id>
    <nct_id>NCT00804648</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vistakon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vistakon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares patient symptoms and anterior segment safety in patients treated with
      timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stinging on Instillation</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Break-up Time</measure>
    <time_frame>following 3 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining Grade</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining Count</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by the investigator using a slit lamp, counting the number of spots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoclular Pressure</measure>
    <time_frame>following 3 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basic Schirmer's</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Schirmer's measures basic tear function. The higher the number, the less dry the eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Staining - Nasal Grade</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Staining - Nasal Count</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by investigator using slit lamp and counting number of spots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Staining - Temporal Grade</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Staining - Temporal Count</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>Assessed by investigator using a slit lamp and counting number of spots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>following 3 days of treatment</time_frame>
    <description>The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Glaucoma, Open Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>hemihydrate/maleate/maleate gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maleate/maleate gel/hemihydrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maleate gel/hemihydrate/maleate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hemihydrate/maleate gel/maleate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maleate/hemihydrate/maleate gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maleate gel, maleate, hemihydrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate in Sorbate</intervention_name>
    <description>0.5%</description>
    <arm_group_label>hemihydrate/maleate/maleate gel</arm_group_label>
    <arm_group_label>maleate/maleate gel/hemihydrate</arm_group_label>
    <arm_group_label>maleate gel/hemihydrate/maleate</arm_group_label>
    <arm_group_label>hemihydrate/maleate gel/maleate</arm_group_label>
    <arm_group_label>maleate/hemihydrate/maleate gel</arm_group_label>
    <arm_group_label>maleate gel, maleate, hemihydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol hemihydrate</intervention_name>
    <description>0.5%</description>
    <arm_group_label>hemihydrate/maleate/maleate gel</arm_group_label>
    <arm_group_label>maleate/maleate gel/hemihydrate</arm_group_label>
    <arm_group_label>maleate gel/hemihydrate/maleate</arm_group_label>
    <arm_group_label>hemihydrate/maleate gel/maleate</arm_group_label>
    <arm_group_label>maleate/hemihydrate/maleate gel</arm_group_label>
    <arm_group_label>maleate gel, maleate, hemihydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol maleate gel forming solution</intervention_name>
    <description>0.5%</description>
    <arm_group_label>hemihydrate/maleate/maleate gel</arm_group_label>
    <arm_group_label>maleate/maleate gel/hemihydrate</arm_group_label>
    <arm_group_label>maleate gel/hemihydrate/maleate</arm_group_label>
    <arm_group_label>hemihydrate/maleate gel/maleate</arm_group_label>
    <arm_group_label>maleate/hemihydrate/maleate gel</arm_group_label>
    <arm_group_label>maleate gel, maleate, hemihydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willing to comply with investigator's and protocol's instructions

          -  patients signature on the informed consent document

          -  primary open-angle glaucoma, pigment dispersion or exfoliation glaucoma, or ocular
             hypertension in at least one eye

          -  at screening intraocular pressure must be considered to be safe, in both eyes

          -  in non-qualifying eyes the intraocular pressure should be able to be controlled safely
             on no pharmacologic therapy or on study medicine alone

          -  currently treated with one glaucoma medication, untreated intraocular pressure of less
             than or equal to 28 mm Hg at visit 2 in both eyes

        Exclusion Criteria:

          -  any abnormality preventing reliable applanation tonometry in either eye

          -  any opacity or subject uncooperativeness that restricts adequate examination of the
             ocular fundus or anterior chamber in either eye

          -  any concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either
             eye

          -  any history of allergic hypersensitivity or poor tolerance to any components of the
             preparations used in this trial

          -  females of childbearing potential not using reliable means of birth control

          -  pregnant or lactating females

          -  any clinically significant, serious, or severe medical or psychiatric condition

          -  participation (or current participation) in any investigational drug or device trial
             within 30 days prior to Visit 1

          -  severe prior visual acuity or field loss from any cause

          -  inability to understand the trial procedures, and thus inability to give informed
             consent

          -  progressive retinal or optic nerve disease apart from glaucoma

          -  serious systemic or ocular disease

          -  intraocular laser surgery within the past three months or corneal or intraocular
             conventional surgery within the past 6 months

          -  concurrent use of systemic corticosteroids, by IV, oral, dermal or topical ophthalmic
             route.

          -  subjects requiring tear replacement drops or allergy medications with sympathomimetics
             24 hours prior to a scheduled study visit

          -  contraindication to beta-blocker usage including: reactive airway disease,
             uncontrolled heart failure, or second as well as third degree cardiac block,
             myasthenia gravis

          -  any subject the investigator believes will be at risk for glaucomatous progression by
             their participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C. Stewart, MD</last_name>
    <role>Study Director</role>
    <affiliation>PRN Pharmacuetical Research Network, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bourbonnais</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <results_first_submitted>September 1, 2010</results_first_submitted>
  <results_first_submitted_qc>October 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2010</results_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hemihydrate/Maleate/Maleate Gel</title>
          <description>Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%</description>
        </group>
        <group group_id="P2">
          <title>Maleate/Maleate Gel/Hemihydrate</title>
          <description>Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%</description>
        </group>
        <group group_id="P3">
          <title>Maleate Gel/Hemihydrate/Maleate</title>
          <description>Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%</description>
        </group>
        <group group_id="P4">
          <title>Hemihydrate/Maleate Gel/Maleate</title>
          <description>Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%</description>
        </group>
        <group group_id="P5">
          <title>Maleate/Hemihydrate/Maleate Gel</title>
          <description>Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%</description>
        </group>
        <group group_id="P6">
          <title>Maleate Gel/Maleate/Hemihydrate</title>
          <description>Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Invervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stinging on Instillation</title>
        <description>Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Stinging on Instillation</title>
          <description>Assessed from subject response to survey question asking about tolerability of medicine upon instillation, using a 0 through 7 scale, with 0=complete comfort and 7=worst pain imaginable.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.0" spread="1.4"/>
                    <measurement group_id="O3" value="0.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperemia</title>
        <description>Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Hyperemia</title>
          <description>Assessed by investigator using a slit lamp and a photographic grading scale. Photographs were graded: grade 0, grade 1, grade 2, grade 3. The higher the graded the worse the hyperemia.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.4" spread="0.5"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Film Break-up Time</title>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Break-up Time</title>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="6.1"/>
                    <measurement group_id="O2" value="7.7" spread="4.9"/>
                    <measurement group_id="O3" value="8.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining Grade</title>
        <description>Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining Grade</title>
          <description>Assessed by the investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5. The higher the grade the worse the staining.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                    <measurement group_id="O2" value="1.1" spread="0.9"/>
                    <measurement group_id="O3" value="1.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining Count</title>
        <description>Assessed by the investigator using a slit lamp, counting the number of spots.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining Count</title>
          <description>Assessed by the investigator using a slit lamp, counting the number of spots.</description>
          <units>Number of spots</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="12.5"/>
                    <measurement group_id="O2" value="10.4" spread="13.4"/>
                    <measurement group_id="O3" value="8.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoclular Pressure</title>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Intraoclular Pressure</title>
          <units>mm of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="3.1"/>
                    <measurement group_id="O2" value="16.2" spread="2.4"/>
                    <measurement group_id="O3" value="16.2" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basic Schirmer's</title>
        <description>Schirmer's measures basic tear function. The higher the number, the less dry the eye.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Basic Schirmer's</title>
          <description>Schirmer's measures basic tear function. The higher the number, the less dry the eye.</description>
          <units>mm of moisture</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="9.7"/>
                    <measurement group_id="O2" value="14.8" spread="7.3"/>
                    <measurement group_id="O3" value="15.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Staining - Nasal Grade</title>
        <description>Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining - Nasal Grade</title>
          <description>Assessed by investigator using a slit lamp and the Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.9"/>
                    <measurement group_id="O2" value="1.1" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Staining - Nasal Count</title>
        <description>Assessed by investigator using slit lamp and counting number of spots.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining - Nasal Count</title>
          <description>Assessed by investigator using slit lamp and counting number of spots.</description>
          <units>number of spots</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="12.5"/>
                    <measurement group_id="O2" value="10.3" spread="15.7"/>
                    <measurement group_id="O3" value="12.9" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Staining - Temporal Grade</title>
        <description>Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining - Temporal Grade</title>
          <description>Assessed by investigator using a slit lamp and Oxford Scheme, grading 0,1,2,3,4,5 according to pictures provided. The higher the grade the worse the staining.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.6"/>
                    <measurement group_id="O2" value="0.7" spread="0.7"/>
                    <measurement group_id="O3" value="0.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Staining - Temporal Count</title>
        <description>Assessed by investigator using a slit lamp and counting number of spots.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Staining - Temporal Count</title>
          <description>Assessed by investigator using a slit lamp and counting number of spots.</description>
          <units>number of spots</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="7.3"/>
                    <measurement group_id="O2" value="4.8" spread="8.6"/>
                    <measurement group_id="O3" value="5.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Acuity</title>
        <description>The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.</description>
        <time_frame>following 3 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Timolol Hemihydrate 0.5%</title>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
          </group>
          <group group_id="O3">
            <title>Timolol Maleate Gel Forming Solution 0.5%</title>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>The visual acuity score is a count of the number of letters the subject successfully read from the eye chart. The higher the score, the better the vision.</description>
          <units>number of letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="5.6"/>
                    <measurement group_id="O2" value="52.5" spread="6.1"/>
                    <measurement group_id="O3" value="51.4" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Timolol Hemihydrate 0.5%</title>
        </group>
        <group group_id="E2">
          <title>Timolol Maleate 0.5%</title>
        </group>
        <group group_id="E3">
          <title>Timolol Maleate Gel Forming Solution 0.5%</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submission for publication or presentation, the PI will provide the Sponsor with at least 60 days for review of a manuscript. If requested in writing, the PI will withhold publication for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arthur Shedden MD</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-1557</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

